Ferrara James Lm, Smith Christopher M, Sheets Julia, Reddy Pavan, Serody Jonathan S
Departments of Medicine, Pediatrics, and Academic Informatics and Technology, Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, New York, New York, USA.
University of North Carolina Hospital, Chapel Hill, North Carolina, USA.
J Clin Invest. 2017 Jun 30;127(7):2441-2451. doi: 10.1172/JCI90592. Epub 2017 Jun 5.
Lower gastrointestinal (GI) tract graft-versus-host disease (GVHD) is the predominant cause of morbidity and mortality from GVHD after allogeneic stem cell transplantation. Recent data indicate that lower GI tract GVHD is a complicated process mediated by donor/host antigenic disparities. This process is exacerbated by significant changes to the microbiome, and innate and adaptive immune responses that are critical to the induction of disease, persistence of inflammation, and a lack of response to therapy. Here, we discuss new insights into the biology of lower GI tract GVHD and focus on intrinsic pathways and regulatory mechanisms crucial to normal intestinal function. We then describe multiple instances in which these homeostatic mechanisms are altered by donor T cells or conditioning therapy, resulting in exacerbation of GVHD. We also discuss data suggesting that some of these mechanisms produce biomarkers that could be informative as to the severity of GVHD and its response to therapy. Finally, novel therapies that might restore homeostasis in the GI tract during GVHD are highlighted.
下消化道移植物抗宿主病(GVHD)是异基因干细胞移植后GVHD导致发病和死亡的主要原因。近期数据表明,下消化道GVHD是一个由供体/宿主抗原差异介导的复杂过程。微生物群的显著变化以及对疾病诱导、炎症持续和治疗反应缺乏至关重要的固有免疫和适应性免疫反应会加剧这一过程。在此,我们讨论对下消化道GVHD生物学的新见解,并关注对正常肠道功能至关重要的内在途径和调节机制。然后,我们描述了这些稳态机制被供体T细胞或预处理疗法改变从而导致GVHD加剧的多种情况。我们还讨论了一些数据,这些数据表明其中一些机制会产生生物标志物,这些生物标志物可能有助于了解GVHD的严重程度及其对治疗的反应。最后,重点介绍了可能在GVHD期间恢复胃肠道稳态的新型疗法。